After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Most recently, Yahoo Finance reported about the stock as it publicized that Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
AKRO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $20.89 and fluctuated between $21.65 as its day high and $20.36 as its day low. The current market capitalization of Akero Therapeutics Inc is $1.16B. A total of 0.72 million shares were traded on the day, compared to an average of 1.10M shares.
Insider Activity
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, AKRO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 20 BUYs and 53 SELLs from insiders. Insiders purchased 454,735 shares during that period but sold 421,727.
In the most recent transaction, Young Jonathan sold 5,414 shares of AKRO for 24.00 per share on Dec 27. After the transaction, the Chief Operating Officer now owns 185,131 company shares. In a previous transaction on Dec 14, Cheng Andrew sold 1,628 shares at 20.76 per share. AKRO shares that President and CEO owns now total 550,911.
Among the insiders who sold shares, White William Richard disposed of 611 shares on Dec 14 at a per-share price of $20.76. This resulted in the Chief Financial Officer holding 50,354 shares of AKRO after the transaction. In another insider transaction, Yale Catriona sold 597 shares at $20.76 per share on Dec 14. Company shares held by the Chief Development Officer now total 77,910.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for AKRO in the last 3 months, the mean price target is $42.88 with high estimates of $60.00 and low estimates of $33.00. In terms of 52-week highs and lows, AKRO has a high of $58.38 and a low of $11.25.
As of this writing, AKRO has an earnings estimate of -$0.86 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.67 per share and a lower estimate of -$1.09. The company reported an EPS of -$0.6 in the last quarter, which was 4.80% higher than expectations of -$0.63.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. AKRO’s latest balance sheet shows that the firm has $188.26M in Cash & Short Term Investments as of fiscal 2021. There were $1.52M in debt and $25.13M in liabilities at the time. Its Book Value Per Share was $10.47, while its Total Shareholder’s Equity was $169.11M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for AKRO is Buy with a score of 5.00.
